Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) EPS (Basic) (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed EPS (Basic) for 8 consecutive years, with -$0.79 as the latest value for Q1 2026.

  • Quarterly EPS (Basic) fell 17.91% to -$0.79 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$3.17 through Feb 2026, down 13.21% year-over-year, with the annual reading at -$3.05 for FY2025, 5.9% down from the prior year.
  • EPS (Basic) for Q1 2026 was -$0.79 at Nurix Therapeutics, up from -$0.83 in the prior quarter.
  • The five-year high for EPS (Basic) was -$0.45 in Q2 2023, with the low at -$1.03 in Q3 2025.
  • Average EPS (Basic) over 5 years is -$0.77, with a median of -$0.76 recorded in 2024.
  • The sharpest move saw EPS (Basic) plummeted 68.33% in 2022, then surged 55.45% in 2023.
  • Over 5 years, EPS (Basic) stood at -$0.86 in 2022, then rose by 10.47% to -$0.77 in 2023, then rose by 2.6% to -$0.75 in 2024, then dropped by 10.67% to -$0.83 in 2025, then rose by 4.82% to -$0.79 in 2026.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at -$0.79, -$0.83, and -$1.03 for Q1 2026, Q4 2025, and Q3 2025 respectively.